On Thursday, Oppenheimer maintained its Outperform rating and $60.00 price target for Corbus Pharmaceuticals (NASDAQ:CRBP). The firm's stance came after Corbus announced its third-quarter results and provided a business update.
Despite a significant drop in the stock price following competitor Novo Nordisk (NYSE:NVO)'s news on monlunabant in mid-September, Corbus shares have still increased 213% year-to-date, outperforming the XBI's 15% gain. This growth is largely attributed to the promising developments in their ADC program, particularly CRB-701.
Corbus's ADC program, which focuses on the drug CRB-701, is seen as a potentially leading treatment targeting nectin-4. The company is expected to provide a data update in the first quarter of 2025. Additional recent data from Corbus on '913, presented at Obesity Week, suggests a possibly unique safety profile for the company's CB1R targeting program. The first patient dosing for this program is scheduled for early next year.
The company reported a strong financial position, with third-quarter ending cash totaling $159 million. This capital is projected to fund operations well into the second half of 2027. Following the review of the company's recent performance, Oppenheimer has updated its model with the actual figures and reiterated the Outperform rating for Corbus.
In other recent news, Corbus Pharmaceuticals continues to progress with its clinical trials, despite some mixed results. The company has completed patient enrollment for the dose escalation trial of CRB-701, a nectin-4-targeting ADC, with data from at least 12 patients expected to be presented early next year. Additionally, an Investigational New Drug (IND) application for CRB-913, a drug that targets CB1r, is anticipated to be filed later this year.
Despite a downturn in the company's shares following the release of underwhelming trial results from Novo Nordisk's drug monlunabant, analysts remain optimistic. Firms such as Oppenheimer, Mizuho (NYSE:MFG) Securities, H.C. Wainwright, and B.Riley have maintained their positive ratings for Corbus, highlighting the potential of CRB-701 in cervical cancer treatment and CRB-913 in weight loss.
The recent trial results have led to some adjustments in stock targets, with B.Riley reducing its price target to $40 from $85 while maintaining a Buy rating. Despite this, Oppenheimer has increased its price target for the company from $80 to $88, following the company's second-quarter results.
InvestingPro Insights
Corbus Pharmaceuticals' (NASDAQ:CRBP) financial health and market performance align with the optimistic outlook presented in the article. According to InvestingPro data, the company's market capitalization stands at $225.4 million, reflecting investor confidence in its potential. The stock's impressive 350.24% price total return over the past year and 213.08% year-to-date return corroborate the article's mention of the 213% increase year-to-date, outperforming the XBI.
InvestingPro Tips highlight that Corbus holds more cash than debt on its balance sheet, which supports the article's statement about the company's strong financial position with $159 million in cash at the end of the third quarter. This solid cash position is crucial for funding operations into 2027, as mentioned in the article.
Additionally, the InvestingPro Tip noting that three analysts have revised their earnings upwards for the upcoming period aligns with Oppenheimer's maintained Outperform rating and $60 price target. This suggests growing confidence in Corbus's future performance, possibly driven by the promising developments in their ADC program and the anticipated data update for CRB-701 in Q1 2025.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Corbus Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.